| Quote
: |
李琳霈,王容容,潘博,唐建清,蔡美,蒋益兰.肝复方联合榄香烯注射液介入治疗肝郁脾虚型中晚期原发性肝癌临床研究[J].湖南中医药大学学报英文版,2017,37(2):192-195.[Click to copy
] |
|
| |
|
|
| This paper
：Browser 1919times Download 622times |
| 肝复方联合榄香烯注射液介入治疗肝郁脾虚型中晚期原发性肝癌临床研究 |
| 李琳霈,王容容,潘博,唐建清,蔡美,蒋益兰 |
| (湖南省中医药研究院附属医院肿瘤科, 湖南 长沙 410006;湖南中医药大学, 湖南 长沙 410208) |
| 摘要: |
| 目的 观察肝复方联合榄香烯注射液经血管介入治疗肝郁脾虚型中晚期原发性肝癌的临床疗效及安全性。方法 将60例肝郁脾虚型中晚期原发性肝癌患者随机分为治疗组和对照组各30例，治疗组采用肝复方联合榄香烯注射液经血管介入治疗，对照组单行化疗栓塞治疗。4周为1个疗程，治疗2个疗程。观察比较两组治疗前后的中医临床症状、瘤体大小变化、生活质量及不良反应。结果 治疗后两组瘤体疗效相当（P>0.05），但治疗组中医证候疗效、生活质量改善均优于对照组（P<0.05），且治疗组不良反应明显低于对照组（P<0.01）。结论 肝复方联合榄香烯注射液介入治疗肝郁脾虚型中晚期原发性肝癌疗效确切，可改善患者临床症状、提高生活质量，安全可行，值得临床推广。 |
| 关键词: 原发性肝癌 肝复方 肝郁脾虚 榄香烯注射液 肝动脉灌注 |
| DOI：10.3969/j.issn.1674-070X.2017.02.021 |
| Received:May 31, 2016 |
| 基金项目:湖南省自然科学基金项目（2016JJ6082）；湖南省中医药管理局重点项目（201634）。 |
|
| Clinical Study of GanFu Prescription Combined with Elemene Injection as Interventional Therapy on Liver Stagnation and Spleen Deficiency Type of Middle or Advanced Primary Liver Cancer |
| LI Linpei,WANG Rongrong,PAN Bo,TANG Jianqing,CAI Mei,JIANG Yilan |
| (Oncology Department, Affiliated Hospital of Hunan Academy of Chinese Medicine, Changsha, Hunan 410006, China;Hunan University of Chinese Medicine, Changsha, Hunan 410208, China) |
| Abstract: |
| Objective To evaluate the clinical efficacy and adverse reactions of GanFu prescription combined with injection as interventional therapy on liver stagnation and spleen deficiency of middle or advanced primary liver cancer. Methods 60 cases of liver stagnation and spleen deficiency type of advanced primary liver cancer patients were randomly divided into treatment group and control group, 30 cases in each group. The treatment group was treated with GanFu Prescription combined with elemene injection as interventional therapy, and the control group was treated with embolism for 2 courses, 4 weeks as one course. The TCM clinical symptoms, the size of tumor, quality of life and adverse reactions before and after treatment in the two groups were observed. Results The effect on tumor in the two groups are equal(P>0.05), but the treatment group in improving TCM symptoms, life of quality is better than the control group(P<0.05). The adverse reaction in treatment group is lower than those in the control group (P<0.01). Conclusion The effect of GanFu prescription combined with injection as interventional therapy on liver stagnation and spleen deficiency of middle or advanced primary liver cancer is obvious, safe and feasible. It is worthy of the clinical promotion. |
| Key words: primary liver cancer GanFu prescription liver stagnation and spleen deficiency elemene injection hepatic artery perfusion |
|
二维码（扫一下试试看！） |
|
|
|
|
